Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
J Am Coll Surg. 2012 Sep;215(3):343-55. doi: 10.1016/j.jamcollsurg.2012.05.025. Epub 2012 Jun 28.
Complete resection of hilar cholangiocarcinoma (HCCA) is a critical determinant of long-term survival. This study validates a previously reported preoperative clinical T staging system for determining resectability of HCCA.
Consecutive patients with confirmed HCCA treated over an 18-year period were included. Patient demographics, preoperative imaging studies, resection type, margin status, lymph node status, histopathologic findings, morbidity, and outcomes were entered prospectively and analyzed retrospectively; changes in these variables over time were assessed. All patients were placed into 1 of 3 stages based on the extent of ductal involvement by tumor, portal vein compromise, or lobar atrophy.
From March 1991 through December 2008, 380 patients were evaluated. Eighty-five patients had unresectable disease; 295 patients underwent exploration with curative intent. One hundred fifty-seven patients underwent resection: 129 (82.2%) had a concomitant hepatic resection and 120 (76.4%) had an R0 resection. Of the 32 actual 5-year survivors (120 at risk), 30 patients (93.8%) had a concomitant hepatic resection. In patients who underwent an R0 resection, concomitant partial hepatectomy, well-differentiated histology, and negative lymph nodes were independent predictors of long-term survival. In the 376 patients whose disease could be staged, the preoperative clinical T staging system predicted resectability (p < 0.001), metastatic disease (p < 0.001), and R0 resection (p = 0.007).
The preoperative clinical T staging system of Blumgart, defined by the radial and longitudinal tumor extent, accurately predicts resectability of HCCA. The full outcomes benefit of resection is realized only if a concomitant partial hepatectomy is performed.
肝门部胆管癌(HCCA)的完全切除是长期生存的关键决定因素。本研究验证了先前报道的用于确定 HCCA 可切除性的术前临床 T 分期系统。
纳入了在 18 年期间接受过确诊的 HCCA 治疗的连续患者。前瞻性地输入了患者的人口统计学数据、术前影像学研究、切除类型、切缘状态、淋巴结状态、组织病理学发现、发病率和结果,并进行回顾性分析;评估了这些变量随时间的变化。所有患者根据肿瘤累及胆管的范围、门静脉侵犯或肝叶萎缩程度,被分为 3 个阶段之一。
1991 年 3 月至 2008 年 12 月,共评估了 380 名患者。85 名患者患有不可切除的疾病;295 名患者接受了以治愈为目的的探查。157 名患者接受了切除:129 名(82.2%)进行了联合肝切除术,120 名(76.4%)进行了 R0 切除。在 32 名实际的 5 年幸存者(120 名有风险)中,30 名患者(93.8%)进行了联合肝切除术。在接受 R0 切除的患者中,联合部分肝切除术、分化良好的组织学和阴性淋巴结是长期生存的独立预测因素。在可分期的 376 名患者中,术前临床 T 分期系统预测了可切除性(p < 0.001)、转移性疾病(p < 0.001)和 R0 切除(p = 0.007)。
Blumgart 的术前临床 T 分期系统,通过肿瘤的径向和纵向范围来定义,准确预测了 HCCA 的可切除性。只有进行联合部分肝切除术,才能实现切除的全部获益。